Logo

Atara Biotherapeutics, Inc.

ATRA

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors… read more

Healthcare

Biotechnology

11 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$8.38

Price

+2.57%

$0.21

Market Cap

$75.505m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-96.4%

EBITDA Margin

-124.6%

Net Profit Margin

-283.4%

Free Cash Flow Margin

-96.4%

EBITDA Margin

-124.6%

Net Profit Margin

-283.4%

Free Cash Flow Margin
Revenue

$23.139m

+17.8%

1y CAGR

+445.1%

3y CAGR

+387.0%

5y CAGR
Earnings

-$9.467m

+127.4%

1y CAGR

+58.5%

3y CAGR

+52.1%

5y CAGR
EPS

-$0.67

+119.1%

1y CAGR

+61.7%

3y CAGR

+55.9%

5y CAGR
Book Value

-$37.312m

$19.997m

Assets

$57.309m

Liabilities

$10.090m

Debt
Debt to Assets

50.5%

1.9x

Debt to EBITDA
Free Cash Flow

-$25.875m

-1.2%

1y CAGR

+30.9%

3y CAGR

+18.4%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases